Wall Street analyst estimates for Cocrystal Pharma, Inc. (COCP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.15 | ||
| 2026-08-13 | $-0.23 | $-0.17 | -39.4% |
| 2026-05-15 | $-0.17 | $-0.15 | -13.3% |
| 2026-03-31 | $-0.17 | $-0.18 | +5.6% |
| 2025-11-14 | $-0.19 | $-0.22 | +13.6% |
| 2025-08-14 | $-0.20 | $-0.30 | +33.3% |
| 2025-05-15 | $-0.23 | $-0.52 | +55.8% |
| 2025-03-31 | $-0.32 | $-0.55 | +41.8% |
Valuation Ratios
| Price / Book | 14.67 |
| EV / EBITDA | -1.55 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $6.6M | $2.0M | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $201000 | $101000 | $50000 | $4.0M | $6.0M | $8.8M | $12.4M | $15.2M | $12.5M | $5.1M |
| Gross Profit | -$201000 | -$101000 | -$50000 | $2.6M | -$4.0M | -$8.8M | -$12.4M | -$15.2M | -$12.5M | -$5.1M |
| Research & Development | $101.7M | $5.8M | $58.6M | $4.0M | $6.0M | $8.8M | $12.4M | $15.2M | $12.5M | $5.1M |
| Selling, General & Admin | $4.1M | $2.4M | $4.4M | $4.9M | $5.6M | $5.4M | $5.7M | $6.0M | $5.3M | $4.0M |
| Operating Expenses | $105.8M | $8.3M | $62.9M | $51.0M | $5.6M | $5.4M | $26.4M | $3.4M | $5.3M | $4.0M |
| Operating Income | -$105.8M | -$8.3M | -$62.9M | -$48.4M | -$9.6M | -$14.2M | -$38.8M | -$18.6M | -$17.9M | -$9.0M |
| EBITDA | -$105.6M | -$7.4M | -$62.5M | -$2.2M | -$9.4M | -$14.0M | -$18.0M | -$21.0M | -$17.4M | -$8.5M |
| Interest Expense | 0 | 0 | 0 | $19000 | $8000 | $4000 | $2000 | 0 | 0 | 0 |
| Pre-tax Income | -$104.3M | -$7.5M | -$62.6M | -$48.2M | -$9.6M | -$14.2M | -$38.8M | -$18.0M | -$17.5M | -$8.8M |
| Income Tax | -$29.4M | -$6.9M | -$13.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$74.9M | -$613000 | -$49.0M | -$48.2M | -$9.6M | -$14.2M | -$38.8M | -$18.0M | -$17.5M | -$8.8M |
| EPS | $-38.17 | $-0.30 | $-21.01 | $-15.78 | $-2.01 | $-1.85 | $-4.77 | $-0.00 | $-1.72 | $-0.78 |
| EPS (Diluted) | $-38.14 | $-0.30 | $-21.01 | $-15.78 | $-2.01 | $-1.85 | $-4.77 | $-0.00 | $-1.72 | $-0.78 |
| Shares Outstanding (Diluted) | $2.0M | $2.0M | $2.3M | $3.1M | $4.8M | $7.7M | $8.1M | $9.7M | $10.2M | $11.3M |
Price
| Price | $1.14 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BOLT · BRTX · CING · DWTX · EVGN · IMNN · IMRN
Explore sector: Healthcare · Biotechnology
More sections of COCP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks